In addition, the accuracy of MELD scores in predicting the natural history of patients with decompensated HBV cirrhosis has not been prospectively determined. Because the natural history of ...

Patients with NASH display decreased mitochondrial ... or hepatic encephalopathy is indicative of progression to decompensated cirrhosis. Steatosis is diffuse in most patients, but can ...

evaluates progression to liver decompensation events in patients with compensated NASH cirrhosis treated with Rezdiffra versus placebo. A positive outcome is expected to support the full ...

Promethera has advanced HepaStem into phase 2a clinical studies in both ACLF and late stage NASH. ACLF is a recently recognized syndrome characterized by acute decompensation (AD) of cirrhosis ...

Decompensated liver cirrhosis, an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic options other than liver transplantation. At 20 months into ...

evaluating the progression to liver decompensation events in patients with well-compensated NASH cirrhosis treated with Rezdiffra compared with placebo. This second outcomes study completed ...

These features make lamivudine a more appropriate treatment compared with IFN for patients with decompensated HBV cirrhosis. The recommended dose of lamivudine is 100 mg daily. Because lamivudine ...